Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 11;15(1):174.
doi: 10.1186/s12967-017-1277-6.

Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC

Soo-Zin Kim-Wanner  1 , Gesine Bug  2 , Juliane Steinmann  2 , Salem Ajib  2 , Nadine Sorg  1 , Carolin Poppe  1 , Milica Bunos  1 , Eva Wingenfeld  1 , Christiane Hümmer  1 , Beate Luxembourg  3 , Erhard Seifried  1   4 , Halvard Bonig  5   6   7
Affiliations

Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC

Soo-Zin Kim-Wanner et al. J Transl Med. .

Abstract

Background: Red blood cell (RBC) depletion is a standard graft manipulation technique for ABO-incompatible bone marrow (BM) transplants. The BM processing module for Spectra Optia, "BMC", was previously introduced. We here report the largest series to date of routine quality data after performing 50 clinical-scale RBC-depletions.

Methods: Fifty successive RBC-depletions from autologous (n = 5) and allogeneic (n = 45) BM transplants were performed with the Spectra Optia BMC apheresis suite. Product quality was assessed before and after processing for volume, RBC and leukocyte content; RBC-depletion and stem cell (CD34+ cells) recovery was calculated there from. Clinical engraftment data were collected from 26/45 allogeneic recipients.

Results: Median RBC removal was 98.2% (range 90.8-99.1%), median CD34+ cell recovery was 93.6%, minimum recovery being 72%, total product volume was reduced to 7.5% (range 4.7-23.0%). Products engrafted with expected probability and kinetics. Performance indicators were stable over time.

Discussion: Spectra Optia BMC is a robust and efficient technology for RBC-depletion and volume reduction of BM, providing near-complete RBC removal and excellent CD34+ cell recovery.

Keywords: Apheresis; Cell processing; RBC-depletion.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
RBC depletion from BM. RBC depletions from BM were performed with Spectra Optia BMC. a CD34+ cell dose (106/kg), RBC dose (mL/kg), and product volume (mL/kg) in unmanipulated BM (grey) and RBC depleted BM (black) are shown (mean ± SEM). b Efficiency of RBC depletion over time as % of RBC volume in RBC depleted vs. starting product. c Efficiency of CD34+ cell recovery over time as number of CD34+ cells in RBC depleted vs. starting product, expressed as %
Fig. 2
Fig. 2
Engraftment data for RBC depleted BM aspirates. a Engraftment for neutrophils was analyzed based on ABO match. Probability of engraftment over time is shown. Median time to engraftment was no different for the groups. b Engraftment for RBCs was analyzed based on ABO match. Probability of engraftment over time is shown. Median time to engraftment was no different for the groups (n for ABO matched/minor/major mismatch: 2/14/10)
Fig. 3
Fig. 3
Effect of CD34+ cell dose in RBC-depleted allogeneic BM products on engraftment velocity for different hematopoietic lineages. Engraftment for neutrophils (diamonds), platelets (triangles) and RBCs (circles) for Spectra Optia BMP is plotted by CD34+ cell dose (×106/kg; X-axis) over time (days post-transplant; Y-axis). RBC depleted allogeneic BM products provided timely engraftment in all lineages. A dose–effect was not apparent
See this image and copyright information in PMC

References

    1. Blin N, Traineau R, Houssin S, de Peffault LR, Petropoulou A, Robin M, et al. Impact of donor–recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16:1315–1323. doi: 10.1016/j.bbmt.2010.03.021. - DOI - PubMed
    1. Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 2013;48:1161–1167. doi: 10.1038/bmt.2013.51. - DOI - PMC - PubMed
    1. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–1040. doi: 10.1182/blood-2015-04-639831. - DOI - PMC - PubMed
    1. Brauninger S, Bialleck H, Thorausch K, Seifried E, Bonig H. Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v. 5.0, a novel, automatic interface-controlled apheresis system: results from the first feasibility trial. Vox Sang. 2011;101:237–246. doi: 10.1111/j.1423-0410.2011.01484.x. - DOI - PubMed
    1. Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H. Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems. Transfusion. 2012;52:1137–1145. doi: 10.1111/j.1537-2995.2011.03414.x. - DOI - PubMed

Publication types

LinkOut - more resources